CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
脐血来源 CAR-T 治疗 1 例造血干细胞移植后复发的 Ph+ 急性淋巴细胞白血病患者
英文原题：CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
查看英文原题
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前人们对利用脐带血制备异基因 CAR-T 细胞兴趣浓厚，但对脐带来源 CAR-T 细胞的反应性和持久性知之甚少。我们报告一例血液病中心患者病例：该患者 Ph+ B 细胞急性淋巴细胞白血病（B-ALL）多次复发，且对 blinatumomab 无应答；异基因造血干细胞移植后接受 ponatinib 治疗期间再次复发，随后接受 brexucabtagene autoleucel 治疗。患者 CAR-T 细胞迅速扩增并实现持久缓解，输注后 6 个月临床状况良好，且未出现移植物抗宿主病。本病例有助于了解脐带来源 CAR-T 细胞的反应性和持久性，并进一步证实异基因脐带血来源 CAR-T 细胞具有潜在应用前景。
展开英文摘要原文
While there is intense interest in the production of allogeneic CAR-T cells from umbilical cord units, little is known about the reactivity and persistence of CAR-T cells of umbilical origin.
We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post-allogeneic hematopoietic stem cell transplantation.
The patient achieved a rapid CAR-T expansion and durable remission presenting in good clinical conditions 6 months post-CAR-T infusion, without manifestations of graft-versus-host disease. The case report provides insight into the reactivity and persistence of CAR-T cells of umbilical origin, confirming the potential promise of allogeneic umbilical cord-derived CAR-T cells.
论文信息
- 作者
- Marra JD、Galli E、Giammarco S、Metafuni E、Minnella G、Fosso F、Marietti S、Sica S
- 单位
- Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.Italy
- 文献类型
- 病例报告
- 期刊
- European journal of haematology2024 Jul
- 原文标识
- PubMed 38644613 · DOI 10.1111/ejh.14217